Literature DB >> 20931632

Motor complications in Parkinson's disease: ten year follow-up study.

Iria Cabo López1, Pedro J García Ruiz, Silvia Vázquez Fernández Del Pozo, Vicenta Sánchez Bernardos.   

Abstract

Parkinson's disease (PD) can be symptomatically controlled with standard treatments; however, after a few years, this response typically declines and most patients develop motor complications. We carried out a prospective practice-based study to evaluate the evolution appearance and evolution of motor complications in 64 de novo PD patients over 5 years and in 38 PD patients over 10 years. We studied untreated patients from initial assessment at basal conditions and evaluated every 6 months thereafter with treatment (levodopa versus other drugs). The follow-up assessments were performed with the Unified Parkinson's Disease Rating Scale (UPDRS). At each assessment, patients were monitored regarding the development of dyskinesias, motor fluctuations, freezing, loss of postural reflexes, and cognitive impairment. We observed a significant improvement in UPDRS scores during the first year, then a progressive decline, more evident after the third year. Motor complications increased after the third year, and at the end of the survey (tenth year); drug-induced dyskinesias and motor fluctuations were experienced (71.1 and 94.7%, respectively). After the first decade, many complications arose from the non-levodopa-responsive features of the disease (cognitive impairment was present in 52.6% and gait freezing in 71.1%). Initial medication may influence medium-term complications but not long-term problems. Most long-term disabling problems of PD were related to non-levodopa-responsive features.
© 2010 Movement Disorder Society.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20931632     DOI: 10.1002/mds.23219

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  27 in total

1.  The role of the prefrontal cortex in freezing of gait in Parkinson's disease: insights from a deep repetitive transcranial magnetic stimulation exploratory study.

Authors:  Moria Dagan; Talia Herman; Anat Mirelman; Nir Giladi; Jeffrey M Hausdorff
Journal:  Exp Brain Res       Date:  2017-05-16       Impact factor: 1.972

Review 2.  Freezing of gait in Parkinson's disease: where are we now?

Authors:  Elke Heremans; Alice Nieuwboer; Sarah Vercruysse
Journal:  Curr Neurol Neurosci Rep       Date:  2013-06       Impact factor: 5.081

3.  Extra-nigral pathological conditions are common in Parkinson's disease with freezing of gait: an in vivo positron emission tomography study.

Authors:  Nicolaas I Bohnen; Kirk A Frey; Stephanie Studenski; Vikas Kotagal; Robert A Koeppe; Gregory M Constantine; Peter J H Scott; Roger L Albin; Martijn L T M Müller
Journal:  Mov Disord       Date:  2014-06-07       Impact factor: 10.338

Review 4.  Normal and pathological gait: what we learn from Parkinson's disease.

Authors:  David Grabli; Carine Karachi; Marie-Laure Welter; Brian Lau; Etienne C Hirsch; Marie Vidailhet; Chantal François
Journal:  J Neurol Neurosurg Psychiatry       Date:  2012-06-29       Impact factor: 10.154

Review 5.  Mesencephalic and extramesencephalic dopaminergic systems in Parkinson's disease.

Authors:  Fanni F Geibl; Martin T Henrich; Wolfgang H Oertel
Journal:  J Neural Transm (Vienna)       Date:  2019-01-14       Impact factor: 3.575

6.  NADPH ameliorates MPTP-induced dopaminergic neurodegeneration through inhibiting p38MAPK activation.

Authors:  Jing-Si Zhou; Zhou Zhu; Feng Wu; Ying Zhou; Rui Sheng; Jun-Chao Wu; Zheng-Hong Qin
Journal:  Acta Pharmacol Sin       Date:  2018-05-16       Impact factor: 6.150

7.  A combined pharmacokinetic/pharmacodynamic model of levodopa motor response and dyskinesia in Parkinson's disease patients.

Authors:  N Simon; F Viallet; A Boulamery; A Eusebio; D Gayraud; J-P Azulay
Journal:  Eur J Clin Pharmacol       Date:  2016-03-03       Impact factor: 2.953

Review 8.  A review of disease progression models of Parkinson's disease and applications in clinical trials.

Authors:  Charles S Venuto; Nicholas B Potter; E Ray Dorsey; Karl Kieburtz
Journal:  Mov Disord       Date:  2016-05-26       Impact factor: 10.338

Review 9.  Imaging: What can it tell us about parkinsonian gait?

Authors:  Nicolaas I Bohnen; Klaus Jahn
Journal:  Mov Disord       Date:  2013-09-15       Impact factor: 10.338

10.  Levodopa-induced dyskinesias in Parkinson's disease increase cerebrospinal fluid nitric oxide metabolites' levels.

Authors:  Bruno L Santos-Lobato; Mariza Bortolanza; Lucas César Pinheiro; Marcelo E Batalhão; Ângela V Pimentel; Evelin Capellari-Carnio; Elaine A Del-Bel; Vitor Tumas
Journal:  J Neural Transm (Vienna)       Date:  2021-12-23       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.